Goldman Sachs raises Bayer stock price target to EUR35 on positive outlook

Published 07/08/2025, 08:54
Goldman Sachs raises Bayer stock price target to EUR35 on positive outlook

Investing.com - Goldman Sachs has raised its price target on Bayer AG (ETR:BAYGN) (ETR:BAYN) (OTC:BAYRY) to EUR35.00 from EUR34.00 while maintaining a Buy rating, following what it considers an overdone market reaction to the company’s second-quarter results.

The German pharmaceutical and agricultural company saw its shares decline 9.9% after reporting its pre-released Q2 2025 results, significantly underperforming the market index which fell 2.8%. Goldman Sachs expressed surprise at the extent of the share price drop, particularly given that the litigation updates provided were viewed as "a positive step forward."

Goldman Sachs made only minor adjustments to its earnings estimates for Bayer, with approximately 1-2% increases in sales and EBITDA projections across 2025-2030. The firm sees "positive risk/reward into 2H’25 newsflow" with 10-25% upside potential versus limited downside if the U.S. Supreme Court accepts the Durnell case.

The investment bank also highlighted potential upside from the OCEANIC-STROKE trial results for asundexian, projecting more than 13% upside versus less than 5% downside depending on positive or negative outcomes. Goldman Sachs expects positive earnings momentum from 2026-2030, driven largely by Bayer’s Pharmaceutical (TADAWUL:2070) division.

Goldman Sachs’ new EUR35 twelve-month target price suggests 40% upside potential from current levels, with the firm citing continued positive sales trajectories for key pharmaceutical franchises including Nubeqa, Kerendia, and the base portfolio as potential catalysts for further growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.